Immix Biopharma shares surge 13.49% premarket after NXC-201 trial shows 75% complete response rate and 2026 BLA submission planned.
ByAinvest
Monday, Dec 8, 2025 4:32 am ET1min read
IMMX--
Immix Biopharma surged 13.49% in premarket trading following the release of robust Phase 2 clinical trial results for its lead candidate NXC-201 in relapsed/refractory AL Amyloidosis, with a 75% complete response rate and potential for 95% efficacy, as presented at ASH 2025. The data, coupled with a planned $100 million equity financing to fund NXC-201 development and a key hire of a former Chimerix executive as Chief Commercial Officer, reinforced investor confidence in the therapy’s commercial potential and regulatory pathway, including a 2026 Biologics License Application submission.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet